As previously reported, Craig-Hallum initiated coverage of Biote (BTMD) with a Buy rating and $12 price target Consumer interest in next-gen therapies like hormone replacement therapy, or HRT, is rising and Biote’s proprietary solution enables family doctors around the country to safely and effectively administer hormone therapy to patients at scale. Growth rate is temporarily depressed to high-single-digits in 2024 given transition of supplement business, but is poised to reaccelerate to double-digit growth in 2025 and beyond, Craig-Hallum argues.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BTMD:
- Biote initiated with a Buy at Craig-Hallum
- Biote Corp. Reports Steady Growth in Q3 2024
- Biote reports Q3 EPS 33c, consensus 9c
- Biote lowers FY24 revenue view to $197M-$201M from $200M-$204M
- Biote Corp. (BTMD) Q3 Earnings Cheat Sheet
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
